Coherus Biosciences | Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Akebia Therapeutics USD 376.56M 12.41M 2025-12
ALKERMES USD 2.49B 157.48M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amarin USD 659.81M 10.31M 2025-09
Amgen USD 90.59B 445M 2025-12
Baxter International USD 20.06B 1.01B 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Coherus Biosciences USD 516.52M 77.05M 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Fujifilm JPY 5.88T 349.29B 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Ironwood Pharmaceuticals USD 396.06M 53.12M 2025-09
Merck USD 129.55B 12.02B 2025-09
Myriad Genetics USD 728.1M 50.8M 2025-09
Pacira USD 1.26B 32.66M 2025-12
Perrigo USD 8.54B 1.55B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Teva Pharmaceutical Industries USD 40.75B 892M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12
Xencor USD 875.5M 6.68M 2025-12
Zoetis USD 15.47B 308M 2025-12


Coherus Biosciences Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.